BOULDER, Colo.--(BUSINESS WIRE)--SomaLogic, Inc., announced today that the National Institutes of Health (NIH) Center for Human Immunology, Autoimmunity and Inflammation (CHI) will use the SOMAscan™ proteomics assay for research with collaborators across the NIH. It is expected that the SOMAscan assay will be installed and fully functional at CHI by the beginning of 2015, under the leadership of CHI Director Neal S. Young, M.D.
“CHI’s mission is to perform cooperative research based on advanced technologies in order to efficiently translate enhanced understanding of immune function and pathophysiology to the clinic,” said Dr. Young. “We believe the SOMAscan assay gives us a powerful new tool to open up proteomics research and biomarker discovery to many more NIH scientists who are performing a wide variety of critical preclinical and clinical studies.”
Help employers find you! Check out all the jobs and post your resume.
